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Objective:  To  study  and compare  the  Japanese  vaccine  policy  with  the policy  in  the  UK  and  to
discuss  factors  that  may  explain  the  gap  in  vaccine  availability  between  the  two countries.
Methods:  We  analysed  approval  and  immunisation  programme  data  from  Japan  and  the  UK
for  20 common  vaccines,  all  of  which  were  approved  and available  from  the  UK  National
Health  Service.
Results: Of  these  20 common  vaccines,  only  four were  introduced  in  Japan.  Of the 16  unap-
proved  vaccines,  11  were  combination  vaccines.  Indications  for  the  other  ﬁve unapproved
vaccines  were  the  prevention  of  infection  with  meningococcus  (3 vaccines)  and  pneumo-
coccus  (2  vaccines).  Coverage  of diphtheria,  tetanus,  pertussis,  and  poliomyelitis  vaccines
was similar  between  the  two  countries  whereas  that  of  measles  and  rubella  was  higher  in
Japan.
Conclusions:  These  results  show  that there  is  still  a large  gap  between  Japan  and  the  UK
regarding  access  to  20 common  vaccines  and  immunisation  programmes.  The  keys  to clos-
ing this  gap  include:  (1)  revision  of  vaccine  regulations,  (2)  amendment  of  vaccine-related
laws  to secure  funding  and  cooperation  between  professionals  and  public  health  authori-
ties, and  (3)  improvement  in  the perception  of  vaccines  among  the general  public  and  mass
media.
 . Introduction
Although many health-related indicators, such as life
xpectancy and the infant mortality rate show that the
ealth situation in Japan is among the best in the world
1],  there is a large gap between Japan and other devel-
ped countries in the use of vaccines to prevent serious
nfections [2].  For example, the 7-valent pneumococcal
onjugate vaccine (PCV) was only recently approved in
apan (October 2009), more than 8 years after its approval
n the UK. Many common vaccines, including those for
easles, mumps, and rubella (MMR), the inactivated
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poliovirus vaccine, and combination vaccines, are not yet
available in Japan. This vaccine gap has major implications
for public health both in Japan and in other countries. From
the perspective of global public health, Japan is cited as
an exporter of infectious diseases to countries that have
those diseases under better control through vaccination
[3]. Global interconnectedness allows infectious diseases
to spread greater distances than ever before.
In the case of meningococcal vaccines, the epidemiol-
ogy of meningococcal meningitis, which has an incidence
of around 1000 cases per year in England and Wales [4],
but only around 10–20 cases per year in Japan [5],  can
explain the vaccine availability gap. In other cases, how-
ever, the characteristics and causes of the vaccine gap are
multifactorial. A large gap between Japan and other devel-
Open access under CC BY-NC-ND license.oped countries still exists regarding access to new drugs
[6,7], despite several important reforms in the Japanese
drug approval system. These included the implementa-
tion of the International Conference on Harmonisation of
ealth PoR. Shimazawa, M. Ikeda / H
Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH) good clinical practice, the
establishment of a new regulatory authority in 1997, and
the implementation of Ethnic Factors in the Acceptabil-
ity of Foreign Clinical Data (ICH E5) guidelines in 1998
[8,9]. Apart from vaccine development and regulation, one
possible cause for the gap relates to the organisation and
funding of the immunisation programme [10]. In Japan, the
immunisation programme is outside the national health
insurance system, whereas in the UK, the immunisation
programme is an important part of the NHS. Funding of the
immunisation programme in Japan [11,12] has historically
been determined by local governments, with the effect of
subsidies being sometimes questionable [13]. The effect of
public perception on vaccine use is another common prob-
lem in developed countries. This is exempliﬁed by the low
MMR  vaccine coverage in the UK following negative pub-
licity about possible links between the vaccine and autism
[14]. The outbreak of pertussis in several US states was
probably caused by perception-related vaccine refusal [15].
The purpose of this study was to identify factors con-
tributing to the vaccine gap between Japan and the UK
and to advocate solutions for overcoming the problem. We
compared data from the vaccine approval and immunisa-
tion programmes of the two countries. We  selected the
UK as a comparator because Japan and the UK have the
following background features in common. First, the UK,
like Japan, provides a National Health Service. Second, both
the UK and Japan offer a non-compulsory immunisation
programme. Third, according to ICH guidelines [16], the
regulation of vaccines is harmonised between Japan and
the EU, of which the UK is a member state. Fourth, both
the UK [14] and Japan [17] suffered the effects of negative
public perception and widespread concern regarding the
MMR  vaccine. These similarities highlight the vaccine gap
and allow us to analyse its causes.
2. Methods
2.1. Study design
Cross-sectional study of documents published on regu-
latory agencies’ websites.
2.2. Data sources
To compare the approval status of vaccines in Japan
with that in the UK, we analysed data on 20 common vac-
cines routinely offered to children or available from the
NHS to adults in certain ‘at risk’ groups. The 20 common
vaccines are all approved in the UK and listed in the elec-
tronic Medicines Compendium (eMC) [18] and European
public assessment reports (EPAR) [19]. European legisla-
tion aims to ensure that the terms by which vaccines are
authorised are harmonised across the EU. The European
Medicines Agency takes responsibility for the authorisation
of vaccines, working with national medicines regulatory
authorities, such as the Medicines and Healthcare products
Regulatory Agency in the UK.
Japanese approval data were obtained from the Phar-
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in the new drug approval section [20], which included a
review of all new molecular entities and biologics approved
in Japan between June 1999 and March 2012. The UK
approval (market authorisation) data were obtained from
the eMC [18]. A more detailed description of the regulatory
review of the vaccines is given in EPAR [19]. The Japanese
immunisation data were obtained from the Infectious Dis-
ease Surveillance Center [21]. The UK immunisation data
were obtained from the NHS Information Centre website
[22].
2.3. Evaluation and analysis
Documents were examined for administrative informa-
tion and the dates and types of regulatory approval were
recorded. Approval delay was deﬁned as the difference
between the date of approval in Japan and that of ﬁrst
authorisation in the UK. Review time was  deﬁned as the
time between the date of application for approval and the
actual date of approval. Because of the limited number of
vaccines analysed, results are presented in a descriptive
manner without statistical interpretation.
3. Results
Table 1 shows approval status data for 20 common
vaccines. Four vaccines, i.e., Haemophilus inﬂuenzae type
b (Hib), bivalent and quadrivalent human papillomavirus
(HPV), and 7-valent PCV, were introduced in Japan 173,
25, 57, and 104 months later, respectively, than in the UK,
whereas the review times for bivalent and quadrivalent
HPV, and 7-valent PCV were longer by only 7, 2, and 9
months, respectively, than those in the UK. Although the
review time for the Haemophilus b conjugate vaccine was
46 months, this is still much shorter than the launch delay
which was  173 months. Of the 16 unapproved vaccines
in Japan, 11 were combination vaccines. Indications of the
ﬁve other unapproved vaccines were for the prevention of
infection with meningococcus (3 vaccines) and pneumo-
coccus (2 vaccines).
Table 2 shows the recommendations for and coverage
of the vaccines. Hib, PCV, mumps, and HPV vaccines, which
are recommended in the UK, are all voluntary in Japan.
Meningococcal vaccines are not available in Japan. The
coverage of diphtheria, tetanus and pertussis (DTP), and
poliomyelitis vaccines was  similar between Japan and the
UK. That of measles and rubella was higher in Japan. No
ofﬁcial coverage data were available for voluntary immu-
nisation in Japan, i.e., for Hib, PCV, and mumps.
4. Discussion
Our study conﬁrmed and characterised the vaccine gap
between Japan and the UK. Two of the 4 vaccines that were
approved by both countries were approved in Japan 173
and 104 months after their approval in the UK, with a
review time of 46 and 25 months, respectively. Although
we could not precisely identify the development time, the
review time cannot explain the launch delay of these vac-
cines. Most of the delay is presumably due to delays in
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Table  1
Approval data on 20 common vaccines in Japan and the UK.a
Generic name Proprietary name Approval
application (Japan)
Date of approval Approval delayb,c Review timeb,d
Japan UK Japan UK
Diphtheria, tetanus and
poliomyelitis
Revaxis NA UA Jun-03
Diphtheria, tetanus,
pertussis and
poliomyelitis
Repevax NA UA Nov-01
Diphtheria, tetanus,
pertussis and
poliomyelitis
Infanrix-IPV NA UA Aug-06
Diphtheria, tetanus,
pertussis, poliomyelitis
and Haemophilus
inﬂuenzae type b
Infanrix-IPV + Hib NA UA Jan-05
Diphtheria, tetanus,
pertussis, poliomyelitis
and Haemophilus
inﬂuenzae type b
Pediacel NA UA Oct-02
Haemophilus inﬂuenzae
typeb
ActHIB Mar-03 Jan-07 Aug-92 173 46
Haemophilus inﬂuenzae
type b and
Meningococcal group C
conjugate
Menitorix NA UA Dec-05
Hepatitis A and Hepatitis B Ambirix NA UA Aug-02 15
Hepatitis A and Hepatitis B Twinrix Adult NA UA Sep-96 14
Hepatitis A and Hepatitis B Twinrix Paediatric NA UA Feb-97 10
Human  papillomavirus
bivalent
Cervarix Sep-07 Oct-09 Sep-07 25 25 18
Human  papillomavirus
quadrivalent
Gardasil Jul-10 Jul-11 Sep-06 57 11 9
Measles, mumps and
rubella (live)
MMRvaxpro NA UA May-06 23
Measles, mumps and
rubella (live)
Priorix NA UA Dec-97
Meningococcal group C
conjugate
Meningitec NA UA Sep-07
Meningococcal group C
conjugate
Menjugate NA UA Mar-10
Meningococcal group A, C,
W135 and Y conjugate
Menveo NA UA Mar-10 16
Pneumococcal 7-valent
conjugate
Prevenar Sep-07 Oct-09 Feb-01 104 25 16
Pneumococcal 10-valent
conjugate
Synﬂorix NA UA Mar-09 14
Pneumococcal 13-valent
conjugate
Prevenar13 NA UA Dec-09 12
NA: not available; UA: unapproved.
a As of March 2012.
b Represented in months.
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d Review time was deﬁned as the time between the date of application
pplication and/or development. The 16 vaccines unap-
roved in Japan provide stronger evidence for the gap.
The term ‘drug lag’ [6,7] describes the launch delay of
ew drugs. Of the 398 new drugs approved either in the US,
he EU, or Japan between 1997 and 2007, 220 (55.3%) were
pproved in Japan [7];  however, the percentage of approval
epended on the therapeutic indication. The vaccine gap,
ith an approval rate only 20% (4/20) in the present study,s outstanding when compared with the much higher anti-
nfectives approval rate (71.4%) [7].
With the exception of meningococcal meningitis, which
as an incidence of only around 10–20 cases per year in Japan and that of ﬁrst authorisation in the UK.
roval and the actual date of approval.
Japan [5,23],  the vaccine gap results from a complex of
regulatory and social problems. We  identify three here.
First, vaccine regulations in Japan remain to be reformed.
There are many stakeholders and governmental organisa-
tions for immunisation programmes and policies, including
the Ministry of Health, Labour and Welfare (MHLW)
Health Service Bureau, the Pharmaceutical and Food Safety
Bureau, the PMDA, and the National Institute of Infectious
Diseases. Nonetheless, there is no organisation or commit-
tee that can gather vaccine data from different areas, assess
and evaluate the collected information, and present a rec-
ommendation to the government. A body that can lead
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Table  2
Comparison of immunisation programme between Japan and the UK.
Japan UK
Recommendation Coverage (%) Recommendation Coverage (%)
Diphtheria, tetanus, and pertussisa Recommended 98 Recommended 93
Poliomyelitisa Recommendedc 99 Recommendedd 93
Haemophilus inﬂuenzae type ba Voluntary ND Recommended 93
Pneumococcala Voluntary ND Recommended 91
Meningococcala NA NA Recommended 91
Measlesb Recommendede 94 Recommendedf 85
Rubellab Recommendede 94 Recommendedf 85
Mumpsb Voluntary ND Recommendedf 85
Human papillomavirus Voluntary ND Recommendedg 87
NA: not available; ND: no ofﬁcial data.
a Coverage among 1-year-olds (%) in 2008–2009.
b Coverage among 2-year-olds (%) in 2008–2009.
c Live attenuated oral vaccine.
d Inactivated vaccine given as a combined vaccine with diphtheria, tetanus, and pertussis.
e
 eligibleMeasles and rubella, but not mumps, given as a combined vaccine.
f Measles, rubella, and mumps  given as a combined vaccine.
g Girls of 12–13 years of age. The number represents the percentage of
multiple organisations and propose immunisation policies
[24] should therefore be established to close the gap. No
regulatory guidelines existed for the clinical development
and approval of vaccines in Japan before May  2010 [25].
The EU [26] and the European Federation of Pharmaceuti-
cal Industries and Associations (EFPIA) [2] have urged the
Japanese government to harmonise clinical, regulatory, and
technical standards for vaccines with the EU, the US, and
the World Health Organization so that foreign vaccines
can be imported and Japanese-produced products can be
exported. An exemplary case is the polio vaccine. Japan still
uses a live vaccine instead of an inactivated one, which has
not been approved despite the fact that the live vaccine
causes several cases of paralysis per year. On December 15,
2010, an association of polio victims submitted a petition
to the MHLW,  calling for approval of the importing of an
inactivated vaccine. A panel of experts within the ministry
also called for such an importation. The ministry’s policy,
however, is to wait for the four domestic makers to develop
an inactivated vaccine. This obvious inaction only deepens
the notion that the ministry may  try to protect domestic
manufacturers’ vested interests [11]. Instead, the ministry
should delegate vaccine-related decisions to a transparent
advisory board [24].
Second, vaccine availability does not provide a single
solution for overcoming the gap. The National Health Ser-
vice in Japan only covers the treatment of diseases, not
their prevention. In the case of vaccines covered by the
Immunization Law [27], DTP, poliomyelitis, measles, and
rubella vaccines are supported by governmental funds and
generally provided free throughout Japan, but this does
not apply to Hib, HPV, PCV, or mumps  vaccines. Some
local governments provide subsidies for these vaccines, but
the ﬁnancing policies and recipients’ charges differ among
these governments [12]. The inevitable consequences are
regional disparities [28]. The Immunization Law should be
revised to cover Hib, HPV, PCV, and mumps  vaccines.
Third is the issue of public perception [29]. In Japan, as
in other developed countries, fear of vaccine-preventable
diseases has waned and the awareness of potential girls receiving the ﬁrst dose.
vaccine-related risks has increased [30]. The history of the
MMR  vaccine in Japan provides a case study showing that
negative public perception threatens vaccine acceptance.
In Japan, a high incidence of aseptic meningitis [17]
followed the introduction of the MMR  vaccine in 1989,
which was then mandatory. The UK NHS replaced the
Urabe mumps  strain, which was associated with aseptic
meningitis, with the Jeryl Lynn strain and avoided the prob-
lem, but the MHLW did not. A huge public outcry ensued,
with a number of lawsuits against the Japanese govern-
ment leading to the withdrawal of the MMR  vaccine in
1993. This incident made regulators extremely wary of
being sued for vaccine-related adverse events. In 1994, the
MHLW revised the Immunization Law, which covered vac-
cines for measles and rubella but not for mumps. Today,
instead of the MMR  vaccine, a combined MR  (measles
and rubella) vaccine is provided, with the mumps  vaccine
being optional. The withdrawal of the MMR  vaccine led
to a decrease in coverage, resulting in the exportation of
measles [3].  This discrimination has also led to a high inci-
dence of mumps-associated complications in Japan [31].
Despite the availability of the MMR  vaccine, the lower cov-
erage rate of measles and rubella in the UK compared with
Japan provides further evidence of the negative effect of
public perception and widespread concern about the asso-
ciation between the MMR  vaccine and autism [14].
Our study has some limitations. First, the cross-sectional
observational design limits the establishment of the cause
of the gap. Second, the study was based on publicly avail-
able data, which do not include subtle issues that were
not captured in the deliberation process. Third, there are
only a limited number of vaccines approved in Japan or in
the UK. This limitation made comparisons between the two
countries less conclusive. Fourth, given the heterogeneity
in the vaccines considered, formal statistical analysis of the
reasons for the gap was not possible.In Japan, the vaccine programme has been planned and
implemented, not on the basis of scientiﬁc evidence, but
in part as a reaction to lawsuits against the government
and media coverage, which has sensationalised the adverse
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Japan has been a leader in the development of vac-
ines, such as those for varicella and cellular pertussis, but
he aforementioned challenges have stagnated the imple-
entation of newly developed vaccines. We  believe our
roposals can contribute to a closure of the vaccine gap. The
essons learned so far have helped vaccine policy take a step
orward in some respects. The UK experience of the MMR
accine and its low coverage in urban areas [14] is a good
esson for health care professionals in Japan to improve
he public perception of vaccines among Japanese citizens
32]. The Relief System for Injury to Health with Vaccina-
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. Conclusions
The present study shows that there is still a large
ap between Japan and the UK regarding access to com-
on  vaccines and immunisation programmes. The keys
o closing this gap include: (1) revision of vaccine reg-
lations, (2) amendment of the vaccine-related laws to
ecure funding and cooperation between professionals and
ublic health authorities, and (3) improvement in the per-
eption of vaccines among the general public and mass
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